Streetbeat News

Analyst Ratings

AXP

Over the past quarter, American Express (NYSE:AXP) has received mixed ratings from analysts, with 5 indifferent, 2 somewhat bearish, 3 bearish, and 1 somewhat bullish. The average 12-month price target for the company is $164.36, a 1.8% decrease from the previous average of $167.38.

Portfolio Pulse from Benzinga Insights

July 06, 2023 | 12:03 pm

REGN

Cantor Fitzgerald analyst Alethia Young has maintained a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and lowered the price target from $815 to $795.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 12:02 pm

SQM

Analysts have provided various ratings for Sociedad Quimica Y Minera (NYSE:SQM) in the last quarter, with 2 bullish, 2 somewhat bullish, and 1 bearish. The company has an average 12-month price target of $88.62, a decrease of 28.1% from the previous average price target of $123.25.

Portfolio Pulse from Benzinga Insights

July 06, 2023 | 12:01 pm

VSTM

Cantor Fitzgerald analyst Alethia Young has reiterated an Overweight rating on Verastem (NASDAQ:VSTM) and maintained a $34 price target.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 12:01 pm

TDG

In the last quarter, TransDigm Gr (NYSE:TDG) received mostly bullish ratings from 12 analysts, with an average price target of $908.5, indicating an upside from the current price of $886.58. This average price target has increased by 13.27% from the previous average of $802.09.

Portfolio Pulse from Benzinga Insights

July 06, 2023 | 12:00 pm

LBPH

Cantor Fitzgerald analyst Alethia Young has reiterated an Overweight rating on Longboard Pharmaceuticals and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 12:00 pm

AUPH

Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 11:59 am

BAM

RBC Capital analyst Geoffrey Kwan has reiterated an Outperform rating on Brookfield Asset Management (NYSE:BAM) and maintained a $43 price target.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 11:56 am

STSS

Sharps Technology, Inc. (NASDAQ: STSS and STSSW), a medical device and drug delivery company, has been featured in Med Tech Outlook as the 'Top Safety Syringe Manufacturer in 2023'. The company is advancing its products from research and development to commercial sales, expected to launch in 2023. The article also highlights Sharps' partnership with Nephron Pharmaceuticals and its next-generation polymer-based prefillable syringe systems.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 11:53 am

APTV

Aptiv's stock has been upgraded from Neutral to Buy by B of A Securities, leading to a rise in its share price.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 11:48 am